When metformin is not enough: Pros and cons of SGLT2 and DPP ‐4 inhibitors as a second line therapy

Diabetes/Metabolism Research and Reviews, EarlyView.

Source: Diabetes/Metabolism Research and Reviews - February 15, 2018 Category: Endocrinology Source Type: research